Clearpoint Neuro is trading 5.28% up at $11.47 in pre-market on October 5, 2026, with no new company-specific announcement identified to explain the move. - The gain follows a steep sell-off after partner uniQure reported its Huntington’s disease therapy missed statistical significance on a primary measure at 48 months. - The setback had raised concerns about future revenue tied to ClearPoint Neuro’s delivery technology. - Monday’s pre-market move may reflect a rebound, but no source directly attributes it to a new catalyst.